XORTX estimates $4.1M equity, meets Nasdaq rules

XORTX Therapeutics Inc. estimates its stockholders’ equity at approximately $4.1 million as of this report, which it believes is above the minimum required for continued listing on the Nasdaq Capital Market.

Rhea-AI Filing Summary

XORTX Therapeutics Inc. estimates its stockholders’ equity at approximately $4.1 million as of this report, which it believes is above the minimum required for continued listing on the Nasdaq Capital Market. This estimate reflects its anticipated stockholders’ equity as of March 31, 2026, the April 13, 2026 closing of its acquisition of Vectus Biosystems Limited’s VB4-P5 asset, and estimated results for the first quarter and early second quarter of 2026.

The company stresses that these figures are preliminary, unaudited and subject to change once full financial closing and review are completed. It cautions that actual results for the three months ended March 31, 2026 could differ materially and that investors should not place undue reliance on this early financial information or forward-looking statements.

Insights

Biotech equity and listing specialist

XORTX preliminarily sees $4.1M equity, indicating Nasdaq compliance.

XORTX Therapeutics currently estimates stockholders’ equity of about $4.1 million, which it believes exceeds the Nasdaq Capital Market’s minimum equity standard for continued listing. The estimate incorporates its March 31, 2026 equity position, the VB4-P5 asset acquisition on April 13, 2026, and early 2026 operating results.

The company emphasizes these numbers are preliminary, unaudited and may change after full quarter-end closing and preparation of its March 31, 2026 financial statements. Forward-looking language highlights risks around ongoing Nasdaq compliance, clinical and preclinical progress, regulatory approvals, intellectual property protection, and liquidity, so the equity estimate should be viewed as an early indicator rather than a finalized figure.

Key Figures

Estimated stockholders’ equity: $4.1 million VB4-P5 asset acquisition closing date: April 13, 2026 Assessment period: Three months ended March 31, 2026

3 metrics

Estimated stockholders’ equity $4.1 million Preliminary estimate as of May 2026, reflecting March 31, 2026 position and VB4-P5 acquisition

VB4-P5 asset acquisition closing date April 13, 2026 Closing of Vectus Biosystems Limited’s VB4-P5 asset, factored into equity estimate

Assessment period Three months ended March 31, 2026 Quarter for which results of operations are included in equity estimate

Key Terms

stockholders’ equity, Nasdaq Capital Market, forward-looking statements, preclinical studies, +2 more

6 terms

stockholders’ equity financial

"currently estimates that its stockholders’ equity is approximately $4.1 million"

Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.

Nasdaq Capital Market financial

"exceeds the minimum stockholders’ equity requirement of the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

forward-looking statements regulatory

"This report on Form 6-K contains express or implied “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

preclinical studies technical

"the success and timing of the Company’s preclinical studies and clinical trials"

Preclinical studies are initial research tests conducted in laboratories and on animals to evaluate the safety, effectiveness, and potential risks of a new medical treatment or drug before it is tested in humans. For investors, these studies are an important early step that can indicate whether a product has the potential to advance toward approval and commercial use, influencing the future prospects and valuation of related companies.

clinical trials technical

"the success and timing of the Company’s preclinical studies and clinical trials"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

liquidity and capital resources financial

"and its liquidity and capital resources"

Liquidity and capital resources describe a company’s ready access to money and funding: liquidity is the cash and assets that can be quickly used to pay bills, while capital resources are the broader pool of funds a business can draw on for operations and growth, including cash, credit lines, and financing options. Investors care because these determine whether a company can meet short-term obligations, survive shocks, and finance future projects—think of liquidity as a household’s checking account and capital resources as its savings, credit cards and loan options combined.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does XORTX (XRTX) report about its current stockholders’ equity?

XORTX currently estimates its stockholders’ equity at approximately $4.1 million. This preliminary, unaudited figure is based on expected equity as of March 31, 2026, the VB4-P5 asset acquisition, and early 2026 operating results, and may change after full financial closing.

How does XORTX’s estimated equity relate to Nasdaq listing requirements?

XORTX believes its estimated $4.1 million in stockholders’ equity exceeds the Nasdaq Capital Market’s minimum equity requirement for continued listing. This suggests ongoing compliance with that specific standard, although broader Nasdaq listing standards and other risks still apply.

Why are XORTX’s May 2026 equity figures described as preliminary?

The company states its stockholders’ equity estimate is preliminary and unaudited. It is subject to change after completing financial closing for the three months ended March 31, 2026, preparing unaudited condensed consolidated financial statements, and making any final adjustments that arise in that process.

What transactions and periods are included in XORTX’s $4.1M equity estimate?

XORTX’s approximate $4.1 million equity estimate considers its expected stockholders’ equity as of March 31, 2026, the April 13, 2026 closing of the VB4-P5 asset acquisition from Vectus Biosystems Limited, and estimated operating results for the first quarter and part of the second quarter of 2026.

What forward-looking risks does XORTX highlight in this Form 6-K?

XORTX notes forward-looking risks related to Nasdaq listing compliance, timing and results of preclinical studies and clinical trials, obtaining regulatory approvals, protecting intellectual property, and its liquidity and capital resources, all of which could cause actual results to differ materially from current expectations.

Does XORTX commit to updating its preliminary equity estimate?

The company states it undertakes no obligation to publicly update or revise its stockholders’ equity estimates or other forward-looking statements, except as required by applicable law. Investors are cautioned not to place undue reliance on this preliminary financial information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW

Calgary, Alberta T2L 2M1

Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x      Form 40-F ¨

As of the date of this report on Form 6-K, based on information currently available, XORTX Therapeutics Inc. (“XORTX” or the “Company”) currently estimates that its stockholders’ equity is approximately $4.1 million, which exceeds the minimum stockholders’ equity requirement of the Nasdaq Capital Market for listing compliance. In making this determination, the Company has considered (i) its estimated stockholders’ equity as of March 31, 2026, (ii) the April 13, 2026 closing of its acquisition of Vectus Biosystems Limited’s VB4-P5 asset, and (iii) its estimated results of operations for the three months ended March 31, 2026 and for the second quarter of 2026 to date.

The estimates of stockholders’ equity set forth in this report are preliminary, unaudited and subject to change. Actual results may differ from these estimates as a result of the completion of the Company’s financial closing processes for the three months ended March 31, 2026, the preparation of its unaudited condensed consolidated financial statements as of and for such period, final adjustments and other developments that may arise between the date of this report and the time such financial statements are finalized. Accordingly, these estimates should not be viewed as a substitute for the Company’s unaudited financial statements as of and for the three months ended March 31, 2026, once available. The Company’s expected results for the three months ended March 31, 2026 could differ materially from the estimates set forth herein and are not necessarily indicative of results to be achieved in any future period. Investors are cautioned not to place undue reliance on this preliminary financial information. The Company undertakes no obligation to publicly update or revise these estimates, except as required by applicable law.

Forward-Looking Statements

This report on Form 6-K contains express or implied “forward-looking statements” within the meaning of applicable securities laws. These forward-looking statements include, without limitation, statements regarding the Company’s belief that it currently satisfies, and will continue to satisfy, the stockholders’ equity continued listing requirement and other applicable listing standards of the Nasdaq Capital Market, the Company’s estimates of stockholders’ equity for the periods described herein, the success and timing of the Company’s preclinical studies and clinical trials, the Company’s plans to develop and commercialize its product candidates, and the Company’s plans to advance research in other kidney disease applications, as well as the Company’s beliefs, plans, goals, objectives, expectations, assumptions, estimates and intentions and other statements that are not historical facts. Forward-looking statements are often identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” and similar expressions.  These forward-looking statements are based on the current expectations, estimates and assumptions of the management of XORTX and are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those described in the forward-looking statements, including, without limitation, those relating to the Company’s ongoing compliance with Nasdaq listing standards; the timing, design and results of its preclinical studies and clinical trials; its ability to develop, obtain regulatory approval for and commercialize its product candidates; its ability to protect its intellectual property; and its liquidity and capital resources. Except as otherwise required by applicable law, XORTX undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC’s website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in the Company’s reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XORTX Therapeutics Inc.
	(Registrant)
Date: May 8, 2026	By:	/s/ Allen Davidoff
	Name:	Allen Davidoff
	Title:	Chief Executive Officer